Listen as Ira M. Jacobson, MD; Paul Y. Kwo, MD; and Tatyana Kushner, MD, MSCE, discuss guideline recommendations for HBV treatment indications, recent data describing the relationship between viral suppression and HBV DNA integration, and more expansive indications for HBV treatment based on virologic considerations.
Are we treating HBV early enough? Is it time to move the goalposts regarding the timing of treatment initiation? What are the potential benefits of earlier treatment?
To answer these questions, Ira M. Jacobson, MD, leads a panel discussion with Tatyana Kushner, MD, MSCE, and Paul Y. Kwo, MD, exploring which patients with HBV we should be treating, including a focus on:
Presenters:
Ira M. Jacobson, MD
Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York
Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at
Mount Sinai
New York, New York
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Link to the full program: https://bit.ly/3R1PMi4
Link to the slides: https://bit.ly/3N5Fpsm